Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruitingRare disease

A study to evaluate the safety and effectiveness of zampilimab in people with idiopathic pulmonary fibrosis

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study aims to evaluate the effectiveness and safety of the drug zampilimab, also known as CHF10067, in people living with idiopathic pulmonary fibrosis. This condition is a type of lung disease where the tissue in the lungs becomes thick and scarred over time, making it harder to breathe. The research will compare different doses of zampilimab, which is given through an intravenous infusion, meaning the medicine is delivered directly into a vein using a liquid solution, against a placebo.

During the initial part of the study, participants will receive either the medication or the placebo for a period of 24 weeks. The study will monitor how the treatment affects lung function, specifically looking at the forced vital capacity, which is the total amount of air a person can exhale after taking a deep breath. Following this period, there is an option to continue in an extended phase of the study for an additional 24 weeks.

The research process

The trial runs in 3 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment phase

    Participation begins with the administration of either zampilimab or a placebo (a substance with no active medicine).

    The zampilimab is given as an intravenous infusion, which means it is delivered directly into a vein through a tube.

    The amount of zampilimab administered is 3000 mg.

    This initial phase lasts for 24 weeks.

  2. Step 2

    Monitoring and evaluation

    Assessments are conducted at weeks 0, 6, 12, 18, 24, and 30 to monitor the effects of the treatment.

    The main measurement focuses on the percent predicted forced vital capacity (ppFVC), which is a test used to check how much air the lungs can hold.

    The primary evaluation of how well the medicine works occurs at week 24.

  3. Step 3

    Extension phase

    An optional extension phase is available after the first 24 weeks.

    This phase lasts for an additional 24 weeks.

    During this time, the treatment remains double-blind, meaning neither the person receiving the treatment nor the medical staff know if zampilimab or the placebo is being used.

Who can join the trial?

10 criteria

  • You must provide written informed consent, which means you agree to take part in the study after being told all the details.
  • You must be male or female and at least 40 years old.
  • The doctor must believe you have a life expectancy (how long a person is expected to live) of at least 1 year.
  • Your body weight must be at least 45 kg.
  • You must have been diagnosed with Idiopathic Pulmonary Fibrosis (IPF), a condition that causes scarring in the lungs, within the last 8 years.
  • A recent High-resolution computed tomography (HRCT), which is a detailed type of X-ray scan used to look at the lungs, must have been done within the last 6 months to confirm your diagnosis.
  • Your Forced Vital Capacity (FVC), which is the total amount of air you can breathe out after taking a deep breath, must be at least 45% of what is expected for a healthy person of your age and size.
  • Your ratio of forced expiratory volume in the first second to FVC must be 0.7 or higher, which measures how much air you can blow out quickly in one second.
  • Your diffusing capacity of the lung for carbon monoxide (DLCO), which measures how well your lungs move oxygen from the air into your blood, must be at least 25% of the expected normal value.
  • Your oxygen saturation (SpO2), which is the amount of oxygen in your blood, must be greater than 90% even when using a nasal cannula (a small tube placed in the nose to provide extra oxygen) at a flow of 4 liters per minute.

Who cannot join the trial?

12 criteria

  • Having a confirmed diagnosis of coeliac disease, which is a condition where the body reacts poorly to gluten.
  • Having a low respiratory tract infection, which is an infection in the lungs or airways, within the last 4 weeks.
  • Experiencing an acute exacerbation of IPF, which means a sudden and rapid worsening of shortness of breath related to your lung disease.
  • Having a current diagnosis or a past history of lung cancer.
  • Having emphysema, a lung condition where the air sacs are damaged, if it covers 50% or more of the lungs or is more widespread than the lung scarring.
  • Needing an organ transplant due to advanced lung scarring within the next 6 months.
  • Having uncontrolled health problems involving the heart, liver, digestive system, kidneys, hormones, metabolism, nervous system, or mental health.
  • Having an active or untreated tuberculosis infection, which is a serious bacterial infection that usually affects the lungs.
  • Using cytotoxic drugs, which are medicines that kill cells, or immunosuppressant drugs, which lower the body's ability to fight infection, within the last 48 weeks.
  • Taking a high dose of corticosteroids, which are powerful anti-inflammatory medicines, for more than 10 days.
  • Having a known hypersensitivity or allergy to any of the inactive ingredients used to make the study medicine.
  • Having a history of a severe allergic or anaphylactic reaction to specific types of proteins used in medical treatments called monoclonal antibodies.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Zampilimab is a medication given through an IV infusion to help study its effects on people with idiopathic pulmonary fibrosis, a condition that causes scarring in the lungs.

What is already known about the treatment

  • Zampilimab

    This medication is an experimental drug currently being studied in clinical trials and is not yet widely available for general medical use. It is administered as a liquid through an intravenous infusion, meaning it is delivered directly into a vein. Classified as a biological therapy, it works at a molecular level by targeting specific proteins to help reduce inflammation and scarring in the lungs. It is being investigated as a potential treatment for idiopathic pulmonary fibrosis, a condition that causes lung tissue to become thick and stiff.

  • 0.9% sodium chloride aqueous solution for IV infusion

    This is a common medical solution, often called saline, used as a placebo in this study to act as a control group. It is a simple mixture of salt and water that is administered through an intravenous infusion into the bloodstream. In medical practice, it is used to maintain fluid balance or as a carrier for other medicines. It does not have a specific mechanism to treat lung disease but is used here to ensure the trial results are accurately compared against a neutral substance.

Investigated diseases

Idiopathic pulmonary fibrosis - This condition involves the development of thick, scarred tissue within the lungs. The exact cause of this scarring is unknown. As the disease progresses, the lung tissue becomes stiff and loses its elasticity. This stiffness makes it increasingly difficult for the lungs to expand and contract properly. Over time, the accumulation of scar tissue interferes with the ability of the lungs to transfer oxygen into the bloodstream.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-514246-37-00Protocol codeCLI-10067AA1-02Estimated enrolment243 patientsSponsorChiesi Farmaceutici S.p.A.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).